**Table IIIs – Cardiac outcomes**

|  |
| --- |
| **CARDIAC OUTCOMES** |
| **Strong Outcomes** |
| **Survival to next therapy (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Lima [5] 2016 | 40 | 30 | 75,0% |
| Hall [8] 2018 | 58 | 39 | 67% |
| David [13] 2019 | 29 | 1 | 3% |
| **Weaning [from MCS] (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Mastroianni [4] 2016 | 14 | 6 | 42,9% |
| David [13] 2019 | 29 | 21 | 72,4% |
| Chung [9] 2019 | 100 | 18/30 | 60,0% |
| **Successfull weaning (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Bernhardt [12] 2019 | 22 | 7 | 31,80% |
| Griffith [6] 2013 | 16 | 1/15 | 6,67% |
| Gaudard [7] 2015 | 40 | 18 | 45,00% |
| **Myocardial Recovery (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Bansal [11] 2016 | 24 | 6 | 25% |
| Boll [14] 2019 | 22 | 4 | 18,20% |
| Bernhardt [12] 2019 | 22 | 7 | 31,80% |
| Bertoglio [15] 2019 | 9 | 3 | 33,33% |
| Griffith [6] 2013 | 16 | 13 | 93,00% |
| Gaudard [7] 2015 | 40 | 16 | 40,00% |
| Chung [9] 2019 | 30 | 30 | 100,0% |
| **Bridge to HTx (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Lima [5] 2016 | 40 | 20 | 50,0% |
| Hall [8] 2018 | 58 | 15 | 25,9% |
| Monteagudo-vela [2] 2019 | 14 | 6 | 42,9% |
| David [13] 2019 | 12 | 1 | 8,3% |
| Chung [9] 2019 | 100 | 47 | 47,0% |
| Bansal [11] 2016 | 24 | 2 | 8,3% |
| Gaudard [7] 2015 | 40 | 3 | 8,0% |
| **Bridge to LVAD (pts)** |
| **First Author, Year** | **Sample size** | **Impella 5.0** | **%** |
| Lima [5] 2016 | 40 | 20 | 50,0% |
| Hall [8] 2018 | 58 | 20 | 34,5% |
| Monteagudo-vela [2] 2019 | 14 | 3 | 21,4% |
| Boll [14] 2019 | 22 | 6 | 27,3% |
| Chung [9] 2019 | 100 | 23 | 23,0% |
| Bernhardt [12] 2019 | 22 | 6 | 36,4% |
| Bertoglio [15] 2019 | 9 | 6 | 66,7% |
| Gaudard [7] 2015 | 40 | 9 | 23,0% |
| Mastroianni [4] 2016 | 14 | 3 | 28,5% |
| Bansal [11] 2016 | 24 | 9 | 37,5% |